Interleukin-10 a prognostic factor in treatment with autologous melanoma vaccine

June 04, 2010

(PHILADELPHIA) Scientists from the Kimmel Cancer Center at Jefferson have found that interleukin-10 production in tumor cells is a possible prognostic factor in patients with advanced melanoma who are treated with autologous melanoma cell vaccine. They are presenting their data at the 2010 ASCO Annual Meeting in Chicago (Abstract #8588).

"High production of interleukin-10 (IL-10) in the tumor cells was associated with worse prognosis after patients receive the vaccine," said Amit Mahipal, M.D., a fellow in Hematology/Oncology at Jefferson Medical College of Thomas Jefferson University, and lead author of the study. "Because it downregulates the T cell-mediated immune response, high IL-10 levels in the tumor microenvironment may decrease the effectiveness of the vaccine."

An autologous cancer vaccine is a treatment created from a patient's own tumor cells. When the vaccine is administered to the patient, it may elicit an immune response and kill the tumor cells. IL-10 is a cytokine that plays a major role in adjusting the degree of immune response. It has previously been shown that high IL-10 levels in the blood indicate progression of metastatic melanoma.

In the study, led by Takami Sato, M.D., professor of Medical Oncology at Jefferson Medical College of Thomas Jefferson University, the researchers evaluated 44 patients with stage III and stage IV melanoma. Tumor cells were extracted from melanoma tissues and preserved for vaccine production. Prior to vaccine production, the researchers separated a small portion of melanoma cells from the tissues. These small portions were then cultured for the production of IL-10. The tumor specimens were used for autologous cancer cell vaccine after modification with a chemical called dinitrophenyl (DNP), which makes tumor cells more foreign to the host immune system.

Overall, the median overall survival for high IL-10 producers was 10.5 months vs. 42 months for low IL-10 producers. The difference in median overall survival was more striking in patients with stage III disease: 9.7 months for high IL-10 producers vs. 84 months for low producers. For stage IV disease, the overall survival for high IL-10 producers was 10.5 months vs. 13.7 months for low producers.

"We think that the vaccine treatment may be more effective if you combine the cancer vaccine with a blockade of IL-10," Dr. Mahipal said.

A specific blockade for IL-10 was already developed and is under investigation by Dr. Sato's group at Thomas Jefferson University.

Thomas Jefferson University

Related Immune Response Articles from Brightsurf:

Boosting chickens' own immune response could curb disease
Broiler chicken producers the world over are all too familiar with coccidiosis, a parasite-borne intestinal disease that stalls growth and winnows flocks.

Cells sacrifice themselves to boost immune response to viruses
Whether flu or coronavirus, it can take several days for the body to ramp up an effective response to a viral infection.

Children's immune response more effective against COVID-19
Children and adults exhibit distinct immune system responses to infection by the virus that causes COVID-19, a finding that helps explain why COVID-19 outcomes tend to be much worse in adults, researchers from Yale and Albert Einstein College of Medicine report Sept.

Which immune response could cause a vaccine against COVID-19?
Immune reactions caused by vaccination can help protect the organism, or sometimes may aggravate the condition.

Obesity may alter immune system response to COVID-19
Obesity may cause a hyperactive immune system response to COVID-19 infection that makes it difficult to fight off the virus, according to a new manuscript published in the Endocrine Society's journal, Endocrinology.

Immune response to Sars-Cov-2 following organ transplantation
Even patients with suppressed immune systems can achieve a strong immune response to Sars-Cov-2.

'Relaxed' T cells critical to immune response
Rice University researchers model the role of relaxation time as T cells bind to invaders or imposters, and how their ability to differentiate between the two triggers the body's immune system.

A novel mechanism that triggers a cellular immune response
Researchers at Baylor College of Medicine present comprehensive evidence that supports a novel trigger for a cell-mediated response and propose a mechanism for its action.

Platelets exacerbate immune response
Platelets not only play a key role in blood clotting, but can also significantly intensify inflammatory processes.

How to boost immune response to vaccines in older people
Identifying interventions that improve vaccine efficacy in older persons is vital to deliver healthy ageing for an ageing population.

Read More: Immune Response News and Immune Response Current Events is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to